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Summary We report the first study of triple-dose immunotherapy with heat-killed
Mycobacterium vaccae (SRL 172) combined with short-course, directly observed
chemotherapy in newly diagnosed pulmonary tuberculosis patients. The study was
carried out in Rosario, Argentina, where single-dose immunotherapy with M. vaccae
has previously been shown effective.
Twenty-two HIV seronegative patients, sputum-positive for tubercle bacilli,ee front matter & 2005
med.2005.09.026
ng author. Tel.: +44 20
ess: johnls@dircon.co.uentered a randomised and partly blinded trial. Twelve patients received injections of
SRL 172 and 10 patients received placebo on days 1, 30 and 60 of chemotherapy. All
patients were followed up clinically, by sputum bacteriology, chest radiography and
haematology. Patients receiving SRL 172 showed faster and more complete clinical
improvement, accelerated disappearance of bacilli from sputum, better radiological
clearance and a more rapid fall in ESR, than did those receiving placebo. Follow-up
continued for a year after therapy and no patient failed treatment or relapsed.
Special investigations included longitudinal assessments of respiratory bursts and
expression of CD11b on separated polymorphonuclear and mononuclear leukocytes.
Tumour necrosis factor alpha (TNF-a) was measured in the supernates of cultured
cells and both TNF-a and interleukin-4 (IL-4) were measured in serum samples.
Immunotherapy recipients showed a significantly faster return towards normal
values in all the immunological parameters, than did placebo recipients. The results
are consistent with a regulatory activity on cellular immunity, reducing the influence
of Th2 and enhancing Th1 to the benefit of the patients. This could allow a reducedElsevier Ltd. All rights reserved.
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D. Dlugovitzky et al.1080period of chemotherapy without loss of efficacy and help to prevent the
development of multi-drug resistance.
& 2005 Elsevier Ltd. All rights reserved.Introduction
The use of a single dose of intradermal, heat-killed
Mycobacterium vaccae (NCTC 11659) SRL172 has
been investigated for the treatment of pulmonary
tuberculosis in a number of countries with variable
results. These studies have recently been re-
viewed.1 An explanation for the different results
from different countries has not yet been found,
but may be related to the well-known differences
in efficacy of BCG vaccine and variations in
interleukin-4 (IL-4) and its splice variant IL-4d2.2
The reagent is very safe and has the potential for
becoming an important addition to the treatment
of tuberculosis. Used together with chemotherapy,
efficacy has been observed in both drug-sensitive
and multi-drug-resistant disease (MDRTB).3–6 In
chronic tuberculosis and MDRTB multiple doses of
M. vaccae have been found to be advantageous.7–11
The use of a single dose of SRL172 in tuberculosis
patients co-infected with the human immunodefi-
ciency virus (HIV) was found to be effective in
Nigeria,12 but not in a larger study in Zambia and
Malawi.13
We have investigated immunological and clinical
parameters associated with three doses of SRL172
given during the intensive phase of short-course
chemotherapy. The study was conducted in Argen-
tina, a country where single doses have been found
to be effective5 and carried out in volunteers with
newly diagnosed pulmonary tuberculosis, serone-
gative for HIV infection, attending Carrasco Hospi-
tal in Rosario. The purpose of the study was to
investigate some parameters of cellular immunity
in a country where the treatment was expected to
be clinically effective. Study size was limited by
the high costs of the investigations planned and the
very small budget available. Because of the special
nature of our study, patients were selected from
those coming from fixed addresses and likely to
keep hospital appointments. Permission for the
study was obtained from the Ethics Committees of
the Universidad Nacional de Rosario and Carrasco
Hospital (10/10/2001).
The immunological parameters measured were
selected from amongst those known to be abnormal
in untreated tuberculosis patients and to be
partially corrected during short course chemother-
apy. This is the first evaluation of these parametersin patients receiving SRL172 with chemotherapy
and comparisons have been made with those
receiving chemotherapy alone and with results
obtained in healthy people.
Mononuclear cells (MN) and polymorphonuclear
neutrophils (PMN) play important roles in host
defence against many infections, including tuber-
culosis. Both cell types not only phagocytose and
kill microbes through the production of reactive
oxygen intermediates (ROI) in their respiratory
bursts,14,15 but also influence the immune response
by modulating cytokine production and immune
cell apoptosis.16,17 In tuberculosis, depressed neu-
trophil and mononuclear responses may contribute
to disease severity and exacerbation.18,19 Studies
on the generation of ROIs and functionally asso-
ciated markers such as the expression of the
integrin CD11b, could provide useful information
on the activity of both MN and PMN cells.Materials and methods
Patients and their treatment
Previously untreated adult patients, aged between
18 and 70 years (38713.5 years) with newly
diagnosed, symptomatic, open pulmonary tubercu-
losis about to receive short course, directly
observed anti-tuberculosis chemotherapy (DOTS)
were admitted to the study. This chemotherapy
consisted of daily isoniazid (H), rifampicin (R),
Ethambutol (E) and pyrazinamide (Z) for an
intensive phase of 2 months followed by daily
isoniazid and rifampicin for a continuation phase of
4 months: 2HREZ/4HR. Initial cultures from each
patient were tested for susceptibility and were
found to be susceptible to these four drugs.
On presentation patients were given a full
clinical examination, a chest X-ray was performed,
sputum samples were taken for smear and culture
for tubercle bacilli and they were tested to exclude
HIV sero-positivity by both ELISA and Western Blot
techniques. The patient’s disease was graded as
moderate or severe following guidelines specified
in previous reports.18 On returning to the hospital
for confirmation of diagnosis, suitable patients
were invited to enter the study. After reading the
patient information sheet and having the study
ARTICLE IN PRESS
Three doses M. vaccae immunotherapy for tuberculosis 1081explained to them, volunteers gave their signed
agreement to participate. There were 22 suitable
volunteers who were randomised into active treat-
ment or placebo groups on the basis of computer
generated random blocks. Twelve patients (all male
aged from 33.1714.8 years) were randomised to
receive three intradermal injections of SRL172
(supplied by SR Pharma PLC, London), and ten
patients (8 male and 2 female aged 36.8712.8
years) received injections of physiological saline, as
placebo. The patients themselves, the radiologists
and the staff carrying out laboratory investigations
were blinded to the arm of the study to which
patients were allocated. Clinicians caring for the
patients knew the treatments that their patients
were receiving, but they exerted no influence on
the data recorded.
Initial chest radiographs were assessed according
to the number of lobes affected, the extent of
lesions and the amount of cavitation, pleural
effusion, etc., and scored on a simple numerical
system. Venous blood samples were obtained for
the initial investigations, the first injections of M.
vaccae or placebo were given and chemotherapy
began.
The SRL172 contained 10mg of heat-killed M.
vaccae (NCTC 11659) suspended in 1.0ml of borate-
buffered (pH 8) physiological saline and the
placebo was the buffer alone. Doses of 0.1ml of
SRL 172 or placebo were given by intradermal
injection over alternating deltoid muscles, on the
first day of chemotherapy, after one month and at
the end of the intensive phase of chemotherapy at
2 months. Ambulatory treatment was administered
throughout, with patients attending Carrasco Hos-
pital at monthly intervals and their local treatment
centres on a daily basis for their drugs.
In addition 12 healthy persons (eight male and
four female; mean age 34714.2 years) living in and
around Rosario gave blood samples to determine
normal values for some of the immunological
investigations. None of these healthy control
persons had previous known contact with tubercu-
losis patients. Other than those five with scars of
previous BCG vaccination, they were skin-test
negative to PPD.Clinical and radiological follow-up
At monthly intervals patients returned to Carrasco
Hospital to be weighed and for clinical assessment
of progress. The clinical status of patients and the
severity of cough were assessed by simple numer-
ical systems on each attendance. At months 1, 2, 4
and 6 sputum samples were taken for repeatedbacteriology and at months 1, 2, 3, 4 and 6 further
blood samples were obtained for laboratory in-
vestigations. Repeated chest X-rays were taken
after months 1, 2, 4 and 6. These were assessed
according to the amount of improvement observed
using a numerical system based on lobes affected
and cavitation, enabling the treatment groups to
be compared.
Laboratory investigations
Sputum samples were examined after staining by
the Ziehl–Neelsen method for acid-fast bacilli and
cultures were set up on Lowenstein–Jensen med-
ium.
Haemoglobin concentration, red and white cell
counts, haematocrits and erythrocyte sedimenta-
tion rates (ESR) were performed on all the blood
samples. Serum was collected from clotted blood
samples taken at months 0, 1, 2 and 3 and white
cells were collected from samples of heparinised
blood taken at the same times for immunological
investigations.
Cell studies
Polymorphonuclear (PMN) and mononuclear (MN)
cells from each heparinised blood sample were
separated over Ficoll–Triyosom gradients. As soon
as the MN were separated, the remaining red cells
in the PMN fraction were lysed with ammonium
chloride, and both PMN and MN cells were washed
three times with phosphate buffered physiological
saline (PBS). Washed cells of both types were
suspended in RPMI 1640 with L-glutamine at
5 103 cells/ml and 250 ml of the suspensions were
distributed into 5ml polystyrene tubes. Duplicate
samples were either unstimulated or, for some
tests, stimulated with 5 ml of a suspension of heat
inactivated H37Rv (1.8 106/ml). They were then
incubated for 20 h at 37 1C in 5% CO2.
Following incubation, culture supernatants were
collected and stored at 70 1C for assessment of
tumour necrosis factor-alpha (TNF-a) concentra-
tion. The cell pellets were washed three times with
PBS and resuspended to their original volume in the
same buffer. These cells were examined for their
respiratory bursts and for the expression of the
surface molecule CD11b (an integrin receptor and
marker of cell activation).
Respiratory bursts. For evaluation of the oxida-
tive activity of each cell type, 100 ml of unstimu-
lated cell suspensions (containing 106 cells) were
placed in 5ml polystyrene tubes and each was
diluted with 0.9ml of PBS. To each tube 25 ml of
dihydro-rhodamine-123 (50 mg/ml) were added and
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for 15min. Then, 10 ml of phorbol myristate acetate
(10 ml/ml) were added to each tube and these were
incubated again for 15min in the 37 1C water bath.
After incubation, the samples were centrifuged at
400g for 5min and the supernatants were dis-
carded. The cells were finally resuspended in
500 ml, and 104 cells were acquired for fluores-
cence-activated-flow-cytometry (FACS). This was
carried out using a FACS-Calibur flow cytometer
with computer-assisted evaluation of data (Cell
Quest software). For each sample, 10,000 events
were acquired with gates drawn around granulo-
cytes for the PMN preparations or for MN for the MN
preparations. Results were expressed as the per-
centage of fluorescent cells, and as the oxidative
index (R). This was calculated by dividing the mean
fluorescence value for stimulated cells by the mean
fluorescence value for unstimulated cells. (The
mean fluorescence intensity is proportional to the
amount of ROI generated.)CD11b expression. For this assessment 100 ml
volumes of the washed and resuspended, unstimu-
lated and H37Rv-stimulated cells were taken and
10 ml of anti-CD11b (Immunotech) were added to
each tube. The tubes were incubated for 15min at
room temperature after which the cells were
washed and resuspended again in PBS for flow
cytometry. An isotype control was included
and for each sample 10,000 events were
acquired. The percentage of cells expressing
CD11b and their mean fluorescence intensities
were recorded.TNF-a production. The supernatants of unstimu-
lated MN and PMN cells collected and stored at
70 1C were assessed for TNF-a concentration using
ELISA kits (R&D Systems).Table 1 Body weight increases (mean7SD).
Month M. vaccae
treated (kg)
Placebo
M0 54.7575.77 57.072.91Serum cytokine measurements
To determine the amounts of TNF-a and IL-4 in
serum, the samples stored at 70 1C were thawed
and ELISA kits (R&D Systems) were used following
the manufacturers instructions.M1 56.6775.93 57.872.66
M2 58.5875.78 58.672.63
M4 60.8375.80 59.572.64
M6 61.3875.87 59.072.61
Change Po0:02 n.s.
Wt. Increase 6.6372.4 2.071.08
Po0:001
*Paired Student’s t-test (between M0 and M6).Statistical analyses
The Kruskal–Wallis, Mann–Whitney, Friedman, Stu-
dent’s t-test and Fisher’s exact tests were used in
different parts of our study. The level of statistical
significance was set at Po0:05.Results
Clinical findings
Of the 12 patients randomised to receive SRL172,
ten had disease initially graded as severe and two
had moderate disease. In the placebo group, seven
had severe disease and three had moderate
disease.
During the study, all patients improved in their
clinical status, according to the scoring system
used, with the greatest improvement found
amongst immunotherapy recipients (Po0:001).
Notably, severity of cough reduced fastest amongst
the immunotherapy recipients. All patients showed
recovery of body weight (Table 1): 6.6 kg for M.
vaccae recipients and 2.0 kg for the placebo group
at 6 months (Po0:001 for the difference).Radiological findings
Chest X-rays were available for most time-points
for 10=12 recipients of SRL172 and for 8=10 placebo
recipients. Both patient groups showed significant
radiological improvement with time, with a Fried-
man test value of P ¼ 0:007. The numerical system
used showed that improvement was better in the
SRL172 recipients than in placebo recipients by the
Mann–Whitney U-test P ¼ 0:014 at 2 months and
P ¼ 0:006 at 4 months.Bacteriological findings
All patients admitted to the study were positive for
acid-fast bacilli in their sputum (entry criterion)
and all were culture positive for tubercle bacilli
(Table 2). Those receiving SRL172 showed signifi-
cantly faster disappearance of bacilli by smear
(Po0:03) and culture (0.05) than did placebo
ARTICLE IN PRESS
Table 2 Sputum bacteriology results.
Month Smear +ve Culture +ve
M. vaccae Placebo M. vaccae Placebo
M0 12/12 10/10 12/12 10/10
M1 0/12 Po0.03 4/10 2/12 Po0.05 6/10
M2 0/12 Po0.03 4/10 1/12 Po0.05 5/10
M4 0/12 0/10 0/12 0/10
Fisher’s exact test.
Table 3 Erythrocyte sedimentation rate (mm in
the first hour, means7SD).
Month M. vaccae
treated
Placebo
M0 75.58731.35 n.s. 99.6740.12
Po0:001 Po0:05
M1 28.08719.17 Po0:001 64.9723.46
Po0:005 Po0:001
M2 8.3373.39 Po0:001 19.977.84
Po0:02 Po0:005
M3 5.1771.95 Po0:01 8.372.50
Po0:005 Po0:001
M4 2.7570.87 Po0:01 4.270.92
n.s. n.s.
M6 2.5870.10 Po0:01 3.971.37
Student’s t-test.
Three doses M. vaccae immunotherapy for tuberculosis 1083recipients after 2 months of treatment (Fisher’s
exact test).
Haematological findings
At diagnosis both patient groups had marginally
reduced haemoglobin concentrations, red cell counts
and haematocrit values, which corrected with time
with all patients having normal values by the end of
treatment. Leukocyte counts were slightly raised and
remained so throughout treatment.
ESR (Table 3) fell to normal values in both groups,
though the fall was much faster in SRL172 recipi-
ents (by 63% compared with 35% in the first month;
Po0:001 by Student’s t-test).
Immunological findings
Cell studies
Respiratory bursts (Table 4). Samples of both cell
types from the placebo-group showed a small, but
significant (Po0:001), increase in oxidative index
(R value) with length of treatment. From the
immunotherapy group, PMN cells showed a small
increase over the month following the first injec-
tion of SRL172, and a marked increase a month
after the second injection (Po0:005), which was
also greatly increased over the placebo value at
this time point (Po0:001). This increase continued
in the month following the third injection, at which
time the mean R value for SRL172 recipients was
4.6571.35, compared with 1.1970.23 for the
placebo group (Po0:001).
The MN cells of the patients responded in a
similar way to their PMN cells, though with the
increase in mean R values among SRL172 recipients
starting after the first injection. A month later their
oxidative indices were significantly greater than
those of the placebo group (Po0:001) and after 3
months of treatment the R value for SRL172
recipients was 5.272.42, compared with
1.6470.68 for the placebo group (Po0:001).
CD11b expression (Table 5). Unstimulated PMN
cells from placebo recipients showed a smallincrease in expression with time (Po0:05), whereas
SRL172 recipients showed a marked increase after
the first injection (Po0:005), with smaller in-
creases after the second and third injections.
Although expression values for PMN cells incubated
with H37Rv were much lower than for unstimulated
cells, similar trends are shown, except that the
increase in SRL 172 recipients is delayed until after
the second injection.
CD11b expression on unstimulated MN cells
approximately doubled over 3 months in placebo
recipients (Po0:001), whereas that of SRL172
recipients almost tripled, the increase being great-
est after the first and second injections. After 3
months, MN cells from the SRL172-treated group
showed much more expression of the marker than
did placebo recipients (56.6675.18 compared with
38.2175.99; Po0:001 for the difference). Again,
expression on MN cells incubated with H37Rv was
much lower than for unstimulated cells, but
showed the same trends.
Cytokine measurements (Table 6). The concen-
trations of TNF-a in supernatants of PMN and MN
cell cultures of placebo recipients showed small
reductions in titre with time. SRL172 recipients
ARTICLE IN PRESS
Table 4 Respiratory bursts of unstimulated PMN and MN cells, shown as R values.
Month PMN cells MN cells
M. vaccae
treated
Placebo M. vaccae
treated
Placebo
M0 0.5670.17 n.s. 0.5470.13 0.8970.43 n.s. 0.6870.14
Po0:005 Po0:025 Po0:0001 Po0:0001
M1 0.8870.28 n.s. 0.7070.15 2.0470.71 0.9370.10
Po0:0001 Po0:01 Po0:005 Po0:005
M2 3.2071.28 Po0:0001 0.9270.18 3.3771.10 Po0:0001 1.5170.48
Po0:01 Po0:01 Po0:05 Po0:0001
M3 4.6571.35 Po0:0001 1.1970.23 5.2072.42 Po0:0001 1.6470.68
Suspensions of washed PMN and MN cells separated from heparinised blood and suspended in dilute RPMI medium with
glutamine, were either stimulated with H37Rv, or unstimulated. They were then treated with dihydrorhodamine-123 and
subsequently with phorbol myristate acetate. Resuspended cells were examined by fluorescence-activated cytometry and
results were expressed as percentages of fluorescent cells and as the oxidative index (R mean fluorescence value for stimulated
cells/mean value for unstimulated cells).
Student’s t-test.
Table 5 CD11b expression on unstimulated and H37Rv-stimulated PMN and MN cells cultured for 20 h
(means7esm of % fluorescence intensity).
Month PMN cells MN cells
M. vaccae
treated
Placebo M. vaccae
treated
Placebo
Unstimulated cells
M0 55.86711.33 n.s. 50.8276.63 21.8675.76 n.s. 20.6674.46
Po0:001 Po0:005
M1 82.3779.84 Po0:001 52.6177.87 32.3676.83 Po0:004 23.7473.17
Po0:05 Po0:001
M2 90.6475.74 Po0:001 56.2878.51 53.15715.17 Po0:001 28.0075.79
Po0:025 Po0:005
M3 97.1972.93 Po0:001 56.8775.08 56.6675.18 Po0:001 38.2175.99
Healthy Controls 414.237168.90 154.80786.63
H37Rv-stimulated cells
M0 7.4174.44 n.s. 7.7674.19 4.1670.45 n.s. 3.8770.85
M1 9.9676.61 n.s. 7.7673.56 5.0971.01 n.s. 4.3972.14
Po0:05 Po0:001
M2 17.4677.93 Po0:005 7.3773.17 15.6075.96 Po0:001 4.7571.33
Po0:02
M3 18.6578.10 Po0:001 6.2272.11 19.9475.74 Po0:001 7.0772.19
Healthy controls 229.437183.72 40.98729.58
Student’s t-test.
D. Dlugovitzky et al.1084showed a steep fall of TNF-a in supernates of both
cell types (Po0:001) to near-normal values after 3
months of treatment.
Serological studies (Fig. 1)
Serum levels of both TNF-a and IL-4 were grossly
raised at the beginning of treatment in all patients.The IL-4 values changed relatively little over 3
months in the placebo group, but in SRL 172
recipients both cytokines had returned towards
normal values after 3 months of treatment. Thus
serum TNF-a and IL-4 levels were significantly less
than those of the placebo group at months 1, 2 and
3 (Po0:001).
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Table 6 Production of tumour necrosis factor-a in supernates of unstimulated 20-h cultures of PMN and MN cells
(mean7SD pg/ml).
Month PMN cells MN cells
M. vaccae
treated
Placebo M. vaccae
treated
Placebo
M0 17577193 Po0:001 12807290 21627548 n.s. 18877791
Po0:001 Po0:05
M1 11937263 n.s. 12507292 16417484 P ¼ 0:01 21597332
Po0:001 Po0:05
M2 6067136 Po0:001 12567298 10937488 P ¼ 0:001 21517327
Po0:001 Po0:05
M3 194759 Po0:001 12317283 6147499 Po0:001 21157318
Student’s t-test.
Serum IL-4
0
50
100
150
200
250
300
350
M0 M1 M2 M3
Month
IL
4 
(p
g.m
l-1 )
TNF-α
0
20
40
60
80
100
120
M0 M1 M2 M3
Month
TN
Fα
 
(p
g.m
l-1 )
Placebo
M.vaccae
TBC+HIV
Placebo
M.vaccae
TBC+HIV
Figure 1 Serum IL-4 (upper panel) and TNF-a (lower
panel) values are means7standard deviation in pg/ml.
TNF—was undetectable in the sera of the group of
healthy volunteers and their mean IL-4 value was
56.63734.93 pg/ml. Levels of both cytokines remained
unchanged with time in the placebo recipients (and the
HIV +ve M. vaccae recipients), whereas in the HIV ve M.
vaccae recipients, levels of both cytokines fell sharply in
the first 2 months of treatment (Po0:001), approaching
normal values.
Three doses M. vaccae immunotherapy for tuberculosis 1085Discussion
The results of our very small study suggest that
three doses of heat-killed M. vaccae SRL172 are a
useful addition to DOTS chemotherapy in the
treatment of newly diagnosed pulmonary tubercu-losis. If repeated in a larger trial the effects
observed could result in a faster and more
complete cure. The proof of this requires long-
term follow-up to record relapses, and this is part
of the protocol of the on-going Vietnamese trial21.
Potential benefits of the combined treatment are
shown by the better clearance of bacilli from the
sputum, measured by both Ziehl–Neelsen staining
and culture (Table 2), a faster fall in ESR (Table 3),
and a return towards normal values of plasma TNF-
a and IL-4 (Fig. 1). These reflect better clinical
improvement, improved weight-gain (Table 1) and
better clearance of cavities and opacities in chest
radiographs.
The cell studies showed an increase in the
oxidative index of both PMN and MN cells with
treatment, most notable in recipients of SRL172
(Table 4). Expression of CD11b on both unstimu-
lated or H37Rv-stimulated PMN and MN cells showed
a greater increase in immunotherapy recipients
than in placebo recipients (Table 5), though still far
below normal values. In this test it is difficult to be
entirely certain whether the increased expression
is a direct result of the injections of further
mycobacteria (3 109 M. vaccae), or to the falling
numbers of live tubercle bacilli and the antigen
they release when killed.
Levels of TNF-a in the supernates of unstimulated
PMN and MN cells fell steeply in recipients of
SRL172, whereas they hardly changed in placebo
recipients (Table 6). Together, these results indi-
cate improvements in phagocyte activity and
inimmune regulation of T cell function in immu-
notherapy recipients. The fall in TNF-a with time in
both culture supernatants and serum samples in
those receiving immunotherapy is likely to be an
indication of recovery from the bacterial infection
rather than a reflection of regulation of Th1 (Table
6 and Fig. 1).
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healthy controls are higher than has been the
general experience elsewhere.2 Nonetheless, they
conform with findings in our previous study.5 The
explanation for this may lie in the environment, or
be associated with different distributions of para-
sitic diseases in varying populations. The very high
level of this cytokine in patients receiving SRL172
fell to those of healthy persons, whereas levels
remained unchanged in patients receiving che-
motherapy alone (Fig. 1). Perhaps a raised level
of serum IL-4 may be a marker of those able to
respond to immunotherapy with M. vaccae.
The results of our study strongly support the
evidence of efficacy for combinations of M. vaccae
coming from a number of studies of M. vaccae in
the treatment of newly diagnosed tuberculosis with
either SRL 172 or its Chinese counterpart.1,7 The
possibility exists that these immunological changes
do not take place in countries where immunother-
apy with SRL 172 has been reported to be
ineffective. Our immunological results also provide
an explanation for the efficacy of M. vaccae in the
treatment of chronic and multi-drug-resistant
tuberculosis.11 These conditions have not been
investigated in countries where immunotherapy
has been ineffective in treating simple, newly
diagnosed tuberculosis.
In need of consideration in relation to the results
of treatment with SRL172 obtained in different
areas, is the total environment of the patients.
Geography and climate provide the background to
the agriculture and nutrition determining the
proportions of proteins and carbohydrates in food-
stuffs influencing the gut flora. Different levels of
parasite infestations may occur and different
endogenous viruses may predominate in different
places. Any or all of these are capable of insinuat-
ing a predominantly Th1 or Th2 inclination, and
therefore a vulnerability or resistance to infection.
Treatment via the immune system (and chemother-
apy) would meet with greater resistance in gen-
erally Th2 populations. In many areas a single dose
may be effective but in others multiple doses may
be required. Experience of the use of SRL172 in the
treatment of cancer has found that many repeated
injections are required to overcome the immune
deviating influence of persisting tumour, and the
same is likely to be true in populations heavily
exposed to or parasitised with Th2-promoting
organisms.
The benefits of giving multiple doses of SRL 172
are also illustrated by finding that some changes
were observed only after two or more injections.
Whether these changes would have occurred in
later follow-ups of the recipients of fewer doses hasnot been tested. The earlier return towards normal
values associated with the immunotherapy suggests
that the continuation phase of chemotherapy might
be shortened in patients receiving the combined
treatment.20
This study establishes the value of a three-dose
approach to immunotherapy for tuberculosis with
M. vaccae. Some of the attributes of immunological
success accompanying this immunotherapy are
recorded for the first time in man. Together with
the trial just completing in Vietnam, these studies
may help establish a new regime for the effective
treatment of tuberculosis and allow a significant
reduction in the continuation phase of routine
short-course chemotherapy. The introduction of
such a regime should be effective in preventing the
development of drug resistance and limit the
period of active infection with established MDRTB
strains. It would also reduce the opportunities for
the infection of healthy persons with such strains
and help abort the rise of new ones.Addendum
Three patients with severe tuberculous disease
(two male and one female, aged 26.7711.7 years)
who were excluded from the randomised trial
because they were found to be HIV seropositive
nonetheless wished to receive immunotherapy.
They were treated in the same way as HIV
seronegative patients but were started on treat-
ment with HAART when their treatment for tuber-
culosis began.
Data was available up to 4 months with these
three patients since they did not attend for their 6-
month appointments. Their clinical status improved
during treatment, and their weight increased by
7.773.5 kg. Although they remained smear and
culture positive after 1 and 2 months of treatment,
all three were negative by both criteria after 4
months. ESRs fell at each time point, although they
were still significantly higher than those of both
treatment arms of HIVve patients after 4 months
(13.071.73mm; Po0:001).
The respiratory bursts for PMN cells of HIV+ve
patients behaved as did those of the HIVve
patients receiving chemotherapy only, but their
MC cells behaved as did the M. vaccae-recipient
HIVve patients. Changes in CD11b expression
were intermediate between the two treatment
groups of HIVve patients. Both cell supernate
TNF-a and serum TNF-a and serum IL-4 were raised
to a similar degree to those of HIVve patients and
changed little during treatment.
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HIV+ve tuberculosis patients may benefit from
immunotherapy with M. vaccae, as they were
shown to do in Nigeria.3 HIV serology repeated at
least a year after the third injection of SRL172 in
our patients did not revert to the negativity
observed in a few Nigerian patients.Acknowledgments
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